NZ512040A - Use of GM-CSF to inhibit development of drug resistance in HIV + Patients - Google Patents
Use of GM-CSF to inhibit development of drug resistance in HIV + PatientsInfo
- Publication number
- NZ512040A NZ512040A NZ512040A NZ51204099A NZ512040A NZ 512040 A NZ512040 A NZ 512040A NZ 512040 A NZ512040 A NZ 512040A NZ 51204099 A NZ51204099 A NZ 51204099A NZ 512040 A NZ512040 A NZ 512040A
- Authority
- NZ
- New Zealand
- Prior art keywords
- csf
- hiv
- drug resistance
- patients
- inhibit development
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
A method for inhibiting the development of drug resistance in an HIV positive patient comprising administering granulocyte-macrophage colony stimulating factor (GM-CSF) to the patient, in conjunction with one or more anti-HIV drugs. In particular embodiments, GM-CSF is administered in conjunction with one or more anti- retroviral agents selected from nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors. Advantageously, GM-CSF is added to the initial treatment regimen with the antiretroviral drug(s).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18778498A | 1998-11-06 | 1998-11-06 | |
| PCT/US1999/024857 WO2000027196A1 (en) | 1998-11-06 | 1999-10-22 | Use of gm-csf to inhibit development of drug resistance in hiv+ patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ512040A true NZ512040A (en) | 2004-03-26 |
Family
ID=22690455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ512040A NZ512040A (en) | 1998-11-06 | 1999-10-22 | Use of GM-CSF to inhibit development of drug resistance in HIV + Patients |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1124418A4 (en) |
| JP (1) | JP2002529377A (en) |
| AU (1) | AU763289C (en) |
| CA (1) | CA2349592A1 (en) |
| NZ (1) | NZ512040A (en) |
| WO (1) | WO2000027196A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
| JPH0764742B2 (en) * | 1985-11-27 | 1995-07-12 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | Composition for treating AIDS disease |
| US5198417A (en) * | 1985-11-27 | 1993-03-30 | Genetics Institute, Inc. | Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors |
-
1999
- 1999-10-22 EP EP99971663A patent/EP1124418A4/en not_active Withdrawn
- 1999-10-22 WO PCT/US1999/024857 patent/WO2000027196A1/en not_active Application Discontinuation
- 1999-10-22 AU AU12252/00A patent/AU763289C/en not_active Ceased
- 1999-10-22 CA CA002349592A patent/CA2349592A1/en not_active Abandoned
- 1999-10-22 JP JP2000580445A patent/JP2002529377A/en active Pending
- 1999-10-22 NZ NZ512040A patent/NZ512040A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1124418A4 (en) | 2004-05-26 |
| AU763289B2 (en) | 2003-07-17 |
| WO2000027196B1 (en) | 2000-10-12 |
| AU1225200A (en) | 2000-05-29 |
| WO2000027196A8 (en) | 2000-08-31 |
| AU763289C (en) | 2004-04-29 |
| CA2349592A1 (en) | 2000-05-18 |
| EP1124418A1 (en) | 2001-08-22 |
| WO2000027196A1 (en) | 2000-05-18 |
| JP2002529377A (en) | 2002-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60022021D1 (en) | Preparations containing apomorphine and sildenafil and their use for the treatment of erectile dysfunction | |
| HUP0103423A2 (en) | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection | |
| HUP0100092A2 (en) | Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection | |
| Fox | The modern management and therapy of pulmonary tuberculosis | |
| Merigan | Treatment of AIDS with combinations of antiretroviral agents | |
| James | Saquinavir (Invirase): first protease inhibitor approved--reimbursement, information hotline numbers | |
| BR0317095A (en) | Use of a combination containing a non-nucleoside (nnrti) reverse transcriptase inhibitor with a cytochrome p450 inhibitor such as protease inhibitors | |
| Leitze et al. | Nevirapine-induced hepatitis treated with corticosteroids? | |
| NZ512040A (en) | Use of GM-CSF to inhibit development of drug resistance in HIV + Patients | |
| BR0212917A (en) | Method for Treatment of Hepatitis C Virus Infection in Non-Responding Patients | |
| DE60204694D1 (en) | COMBINATION THERAPY FOR THE TREATMENT OF HEART FAILURE | |
| Bennett et al. | The heroin ulcer: new addition to the differential diagnosis of ulcers of the penis | |
| Rochelle et al. | Potentiation of antihypertensive therapy by use of chlorothiazide | |
| DK1143976T3 (en) | Beta-D-2 ', 3'-didehydro-2', 3'-dideoxy-5-fluorocytidine for use in the treatment of HIV infections | |
| KR950702838A (en) | Method for inhibiting HIV replication using IL-4 using interleukin-4 (IL-4) | |
| NO951608L (en) | Use of BHAP Compounds in Combination with Other Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV Infection | |
| Prokopowycz | Agranulocytosis following use of chlorpromazine therapy | |
| Gulanikar et al. | Bullous Erythema Nodosum Leprosum: A Rare Entity | |
| Simmons | Interleukin-2 for the treatment of HIV infection | |
| Rojas‐Burke et al. | The Oregonian | |
| Mascolini | A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations? | |
| Currier | Progress report: prophylaxis and therapy for MAC | |
| Lopez-Lazaro et al. | Acute myocardial infarction associated with sildenafil | |
| James | Delavirdine (Rescriptor) approved | |
| Mirken | Post-exposure prophylaxis: Still more questions than answers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: SCHERING AG, US Free format text: OLD OWNER(S): IMMUNEX CORPORATION |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |